相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis
Yin Yang et al.
CLINICAL LUNG CANCER (2022)
Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
Hong-Bo Li et al.
CELL COMMUNICATION AND SIGNALING (2021)
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
Kazushige Wakuda et al.
LUNG CANCER (2021)
Advances in Lung Cancer Driver Genes Associated With Brain Metastasis
Yalin Kang et al.
FRONTIERS IN ONCOLOGY (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis
Charissa A. C. Jessurun et al.
NEURO-ONCOLOGY (2021)
Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases
Tom L. Enright et al.
CLINICAL LUNG CANCER (2021)
Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis-the META-L-BRAIN Study
Viviane Teixeira Loiola de Alencar et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
Xianbin Kong et al.
MOLECULAR MEDICINE REPORTS (2021)
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
Yawen Dong et al.
CANCERS (2021)
Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application
Gang Xiao et al.
IMMUNOTHERAPY (2021)
Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
Geng-wei Huo et al.
OPEN MEDICINE (2021)
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis
Lei Sheng et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases
Charu Singh et al.
JOURNAL OF NEUROSURGERY (2020)
Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study
Matthew J. Shepard et al.
JOURNAL OF NEUROSURGERY (2020)
Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study
Guowei Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Short-Term Efficacy of Different First-Line Chemotherapy Regimens for Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
Bei-Bei Zhang et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
Natasha B. Leighl et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2020)
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Teresa Amaral et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
Jorge Garcia-Gonzalez et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11)
Yunpeng Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)
C. Zhou et al.
ANNALS OF ONCOLOGY (2020)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
Lizza E. L. Hendriks et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M. Gadgeel et al.
LUNG CANCER (2019)
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Lucio Crino et al.
LUNG CANCER (2019)
Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study
Birgitte Bjornhart et al.
ACTA ONCOLOGICA (2019)
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
Ryul Kim et al.
CLINICAL LUNG CANCER (2019)
Lung Cancer
Faria Nasim et al.
MEDICAL CLINICS OF NORTH AMERICA (2019)
Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer
Y. Kudo et al.
ANNALS OF ONCOLOGY (2019)
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases
Diego Cortinovis et al.
ANTICANCER RESEARCH (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1478OResults of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain
L Q Chow et al.
ANNALS OF ONCOLOGY (2019)
1482OOutcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042
A S Mansfield et al.
ANNALS OF ONCOLOGY (2019)
1483PDPembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
S F Powell et al.
ANNALS OF ONCOLOGY (2019)
Management of Brain Metastases in Non-Small-Cell Lung Cancer
Vinicius Ernani et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study
Marina C. Garassino et al.
CANCER RESEARCH (2019)
Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis
Keigo Kobayashi et al.
CLINICAL LUNG CANCER (2018)
Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases
Emily Schapira et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Linda Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Louis Fehrenbacher et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Intracerebral efficacy and tolerance of nivolumab in non small-cell lung cancer patients with brain metastases
Clement Gauvain et al.
LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab
Coraline Dumenil et al.
PLOS ONE (2018)
Early PD-1 blockade improves disease control for NSCLC brain metastases treated with radiosurgery
A. Srivastava et al.
RADIOTHERAPY AND ONCOLOGY (2018)
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer
Muhammad Zubair Afzal et al.
JOURNAL OF THORACIC DISEASE (2018)
Using immunotherapy to boost the abscopal effect
Wilfred Ngwa et al.
NATURE REVIEWS CANCER (2018)
Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases
M. Geier et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Lesion Response and Intracranial Control of Brain Metastases From Non–small Cell Lung Cancer After Stereotactic Radiosurgery or Hypofractionated Radiation Therapy Combined With Checkpoint Inhibitors
B.S. Imber et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases
Kamran A. Ahmed et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
C. Henon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer
H. Ashinuma et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)
O. Molinier et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
SRS versus WBRT for resected brain metastases
Jinbo Yue et al.
LANCET ONCOLOGY (2017)
Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options
Meysam Yousefi et al.
CELLULAR ONCOLOGY (2017)
Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial
Jaap D. Zindler et al.
BMC CANCER (2017)
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2016)
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
Elizabeth Dudnik et al.
LUNG CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Systemic Immunotherapy for the Treatment of Brain Metastases
Justine V. Cohen et al.
FRONTIERS IN ONCOLOGY (2016)
Pathogenesis of Breast Cancer Metastasis to Brain: a Comprehensive Approach to the Signaling Network
Bahrami Tayyeb et al.
MOLECULAR NEUROBIOLOGY (2016)
Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).
Jonathan Wade Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Grit S. Herter-Sprie et al.
JCI INSIGHT (2016)
Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
Jean-Charles Soria et al.
CLINICAL CANCER RESEARCH (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
Deepa Rangachari et al.
LUNG CANCER (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria et al.
JAMA ONCOLOGY (2015)
Chapter 5: Assessing Risk of Bias as a Domain of Quality in Medical Test Studies
P. Lina Santaguida et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2012)
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
F. Barlesi et al.
ANNALS OF ONCOLOGY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
An update on the treatment of CNS metastases in small cell lung cancer
William A. Castrucci et al.
CANCER JOURNAL (2008)
Clinical predictors of metastatic disease to the brain from non small cell lung carcinoma: Primary tumor size, cell type, and lymph node metastases
Amol Mujoomdar et al.
RADIOLOGY (2007)
NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain
Robert M. Prins et al.
JOURNAL OF IMMUNOLOGY (2006)
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy
Y Cao et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control
JP Sheehan et al.
JOURNAL OF NEUROSURGERY (2002)
分享论文
